The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: I where: R6 is -C=C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.
本发明提供了公式I中的6-取代的2,3,4,5-四
氢-1H-
苯并[d]
氮杂
环庚烯作为选择性5-HT2C受体激动剂,用于治疗与5-HT2C相关的疾病,包括肥胖症、强迫症/强迫性障碍、抑郁症和焦虑症:I其中:R6为-C=C-R10,-O-R12,-S-R14或-NR24R25;其他取代基如规范中所定义。